Health Catalyst, Inc. (NASDAQ:HCAT) Insider Sells $37,363.60 in Stock

Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) insider Linda Llewelyn sold 6,442 shares of the company's stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $5.80, for a total value of $37,363.60. Following the completion of the sale, the insider now owns 92,260 shares of the company's stock, valued at approximately $535,108. The trade was a 6.53 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Linda Llewelyn also recently made the following trade(s):

• On Monday, December 16th, Linda Llewelyn sold 6,442 shares of Health Catalyst stock. The shares were sold at an average price of $7.88, for a total transaction of $50,762.96.

Health Catalyst Trading Down 0.2 %

NASDAQ:HCAT traded down $0.01 on Friday, reaching $5.49. 1,776,095 shares of the company's stock were exchanged, compared to its average volume of 867,343. The firm has a market capitalization of $334.06 million, a price-to-earnings ratio of -4.07 and a beta of 1.36. Health Catalyst, Inc. has a 52-week low of $5.35 and a 52-week high of $10.99. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The business has a fifty day moving average of $7.61 and a 200-day moving average of $7.52.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.03). Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The business had revenue of $76.40 million for the quarter, compared to analysts' expectations of $76.27 million. During the same period in the previous year, the company earned ($0.22) earnings per share. Health Catalyst's quarterly revenue was up 3.5% on a year-over-year basis. As a group, analysts expect that Health Catalyst, Inc. will post -0.33 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Harbor Capital Advisors Inc. increased its holdings in Health Catalyst by 21.3% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,764 shares of the company's stock worth $96,000 after purchasing an additional 2,064 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of Health Catalyst by 10.3% during the second quarter. The Manufacturers Life Insurance Company now owns 23,162 shares of the company's stock worth $148,000 after buying an additional 2,164 shares during the period. Creative Planning lifted its stake in Health Catalyst by 13.2% in the third quarter. Creative Planning now owns 21,348 shares of the company's stock worth $174,000 after acquiring an additional 2,486 shares during the last quarter. Quarry LP lifted its stake in Health Catalyst by 59.4% in the second quarter. Quarry LP now owns 7,002 shares of the company's stock worth $45,000 after acquiring an additional 2,610 shares during the last quarter. Finally, Probity Advisors Inc. grew its holdings in Health Catalyst by 13.3% during the 3rd quarter. Probity Advisors Inc. now owns 23,045 shares of the company's stock worth $188,000 after acquiring an additional 2,699 shares in the last quarter. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on HCAT. Piper Sandler reaffirmed an "overweight" rating and set a $12.00 price target (up previously from $11.00) on shares of Health Catalyst in a research report on Tuesday, November 26th. Citigroup reduced their target price on Health Catalyst from $10.50 to $10.00 and set a "buy" rating on the stock in a research report on Friday, January 10th. Evercore ISI increased their price target on Health Catalyst from $8.00 to $10.00 and gave the stock an "outperform" rating in a report on Tuesday, October 8th. Royal Bank of Canada reduced their price objective on shares of Health Catalyst from $9.00 to $7.00 and set a "sector perform" rating on the stock in a report on Wednesday. Finally, Stephens increased their target price on shares of Health Catalyst from $7.00 to $9.00 and gave the stock an "equal weight" rating in a research note on Thursday, November 14th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $11.27.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.